S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
NASDAQ:AVDL

Avadel Pharmaceuticals (AVDL) Stock Price, News & Analysis

$16.84
+0.60 (+3.69%)
(As of 03/27/2024 ET)
Today's Range
$16.26
$16.86
50-Day Range
$12.55
$17.22
52-Week Range
$8.00
$17.47
Volume
355,913 shs
Average Volume
1.31 million shs
Market Capitalization
$1.53 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$22.57

Avadel Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
34.0% Upside
$22.57 Price Target
Short Interest
Bearish
11.56% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.10mentions of Avadel Pharmaceuticals in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$1.09 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.46) to $0.83 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.78 out of 5 stars

Medical Sector

292nd out of 939 stocks

Pharmaceutical Preparations Industry

131st out of 422 stocks

AVDL stock logo

About Avadel Pharmaceuticals Stock (NASDAQ:AVDL)

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

AVDL Stock Price History

AVDL Stock News Headlines

Altcoin FRENZY Alert…
Bitcoin recently crossed the highest price in its 15-year history… Less than 2 years after one of the most vicious crypto market meltdowns we've ever seen! Bitcoin's BOOM also sent shockwaves through the altcoin market, with select coins seeing HUGE moves in a matter of days… Like Fetch.ai, that gained over 350% in just the last 30 days…
AVDL Apr 2024 15.000 call
AVDL Apr 2024 25.000 call
AVDL Apr 2024 10.000 put
Trending Stocks Sent To You In Real Time
Sign up today and get instant access to our next stock alert! You do not want to miss out on this next pick! Our stock picks have been known to soar!
AVDL Mar 2024 5.000 put
Avadel Pharmaceuticals Q4 2023 Earnings Preview
AVDL Jan 2025 20.000 call
Avadel Pharmaceuticals PLC ADR
AVDL Mar 2024 12.500 call
AVDL Sep 2024 10.000 put
AVDL Mar 2024 22.500 put
See More Headlines
Receive AVDL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Avadel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/04/2024
Today
3/27/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:AVDL
Employees
154
Year Founded
2015

Price Target and Rating

Average Stock Price Target
$22.57
High Stock Price Target
$29.00
Low Stock Price Target
$16.00
Potential Upside/Downside
+34.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
7 Analysts

Profitability

Net Income
$-160,280,000.00
Pretax Margin
-574.96%

Debt

Sales & Book Value

Annual Sales
$27.96 million
Book Value
$0.98 per share

Miscellaneous

Free Float
86,954,000
Market Cap
$1.53 billion
Optionable
Optionable
Beta
1.56

Social Links

(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Gregory J. Divis Jr. (Age 57)
    CEO & Director
    Comp: $753.69k
  • Mr. Thomas S. McHugh (Age 59)
    Senior VP, Principal Financial and Accounting Officer & CFO
    Comp: $526k
  • Mr. Richard J. Kim (Age 55)
    Chief Commercial Officer
    Comp: $548.44k
  • Mr. Jerad G. Seurer
    General Counsel & Company Secretary
  • Mr. Gregory J. Davis (Age 59)
    VP of Corporate and Business Development
  • Mr. Mark W. Elrod
    Vice President of Sales
  • Ms. Angie Woods
    Vice President of People & Culture
  • Dr. Jordan S. Dubow M.D. (Age 45)
    Consultant
    Comp: $727.93k
  • Dr. Jason M. Vaughn
    Senior Vice President of Technical Operations
  • Ms. Jennifer Gudeman PharmD
    Senior Vice President of Medical & Clinical Affairs

AVDL Stock Analysis - Frequently Asked Questions

Should I buy or sell Avadel Pharmaceuticals stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avadel Pharmaceuticals in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AVDL shares.
View AVDL analyst ratings
or view top-rated stocks.

What is Avadel Pharmaceuticals' stock price target for 2024?

7 brokerages have issued 12-month target prices for Avadel Pharmaceuticals' shares. Their AVDL share price targets range from $16.00 to $29.00. On average, they anticipate the company's share price to reach $22.57 in the next year. This suggests a possible upside of 34.0% from the stock's current price.
View analysts price targets for AVDL
or view top-rated stocks among Wall Street analysts.

How have AVDL shares performed in 2024?

Avadel Pharmaceuticals' stock was trading at $14.12 at the beginning of 2024. Since then, AVDL shares have increased by 19.3% and is now trading at $16.84.
View the best growth stocks for 2024 here
.

When is Avadel Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our AVDL earnings forecast
.

How were Avadel Pharmaceuticals' earnings last quarter?

Avadel Pharmaceuticals plc (NASDAQ:AVDL) released its earnings results on Monday, March, 4th. The company reported ($0.32) earnings per share for the quarter, missing the consensus estimate of ($0.28) by $0.04. The company earned $19.45 million during the quarter, compared to analysts' expectations of $17.41 million. During the same period in the previous year, the firm earned ($0.44) EPS.

What ETF holds Avadel Pharmaceuticals' stock?

iShares Neuroscience and Healthcare ETF holds 8,651 shares of AVDL stock, representing 2.45% of its portfolio.

What other stocks do shareholders of Avadel Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Avadel Pharmaceuticals investors own include Intelsat (I), Bank of America (BAC), Fossil Group (FOSL), Ciena (CIEN), AMC Entertainment (AMC), Chaarat Gold (CGH), Associated British Foods (ABF), Apollo Global Management (APO), Amarin (AMRN) and Cypress Semiconductor (CY).

Who are Avadel Pharmaceuticals' major shareholders?

Avadel Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include RTW Investments LP (7.74%), Wealth Effects LLC (2.69%), Brandes Investment Partners LP (1.71%), Balyasny Asset Management L.P. (0.87%), Modera Wealth Management LLC (0.67%) and Goldman Sachs Group Inc. (0.54%). Insiders that own company stock include Eric J Ende, Geoffrey Michael Glass, Gregory J Divis, Linda Palczuk, Mark Anthony Mccamish and Thomas S Mchugh.
View institutional ownership trends
.

How do I buy shares of Avadel Pharmaceuticals?

Shares of AVDL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AVDL) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners